Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069449301> ?p ?o ?g. }
- W2069449301 endingPage "4826" @default.
- W2069449301 startingPage "4821" @default.
- W2069449301 abstract "Long before reaching our current understanding of the complex relationship between malignancy and the elements of the coagulation system, it was recognized that patients with cancer were at increased risk for thrombosis. Armand Trousseau first described patients with thrombophlebitis as the presenting sign of a visceral malignancy, later known as Trousseau’s syndrome, which he attributed to a special alteration of the blood. Increased risk of thrombosis is associated with alterations in normal blood flow, injury to the vascular endothelium, and alterations in the constitution of blood, referred to as Virchow’s triad (Table 1). While the resulting hypercoagulable state rarely results in overt disseminated intravascular coagulation, virtually all patients with active malignancy demonstrate some degree of activation of the coagulation cascade. Today, it is recognized that thrombosis and cancer are linked by multiple pathophysiological mechanisms and that tumor biology and coagulation processes are integrally connected (Fig 1). The underlying biologic factors associated with the increased risk of thrombosis in patients with cancer include the activation of thrombin and fibrin formation both directly by the release of procoagulants by tumor cells and indirectly by the activation of endothelial cells, leukocytes, and platelets by cytokines and the production of a factor X-activating cysteine protease, mucinous glycoproteins, and circulating tissue factor–bearing microparticles. The molecular and genomic factors at the interface between malignant cell behavior and the hypercoagulable state in the patient with cancer are discussed in the articles by Boccaccio and Comoglio and by Kasthuri et al in this special issue of the Journal of Clinical Oncology. Venous thromboembolism (VTE) may indicate an occult cancer, may represent a complication of a known malignancy, or complicate hospitalization, surgery, or various systemic cancer treatments. VTE, including deep-vein thrombosis (DVT) and pulmonary embolism (PE), is a serious and potentially life-threatening disorder representing the second leading cause of death in hospitalized patients with cancer, although often demonstrated only at autopsy. In addition, the occurrence of VTE may interrupt needed cancer treatment, even as the use of anticoagulants may result in serious bleeding complications. In addition to the human cost, the economic burden of VTE in patients with cancer is substantial with the average cost of hospitalization for DVT estimated at more than $20,000 and one fourth of patients with cancer with VTE requiring readmission as a result of bleeding or a recurrent VTE. Fortunately, there has been considerable progress not only in our basic understanding of the underlying pathophysiology, but also in the diagnosis of VTE and the options available for the treatment and prevention of thrombosis in patients with cancer. Current guidelines recommend primary prophylaxis in both surgical and medical hospitalized patients and for highly selected ambulatory patients with cancer. The development and validation of clinical risk models and the identification of new biomarkers for the selection of patients at increased risk for VYE represents an active area of research. Likewise, the potential impact of anticoagulation on cancer growth, invasion, metastases, and angiogenesis as well as overall survival continues to be actively investigated. It is essential that the results of ongoing research on underlying mechanisms as well as the optimal treatment Procoagulant activities Fibrinolytic activities" @default.
- W2069449301 created "2016-06-24" @default.
- W2069449301 creator A5039576853 @default.
- W2069449301 creator A5073060840 @default.
- W2069449301 date "2009-10-10" @default.
- W2069449301 modified "2023-10-14" @default.
- W2069449301 title "Cancer, Clots and Consensus: New Understanding of an Old Problem" @default.
- W2069449301 cites W1573083214 @default.
- W2069449301 cites W1863488026 @default.
- W2069449301 cites W1895600627 @default.
- W2069449301 cites W1967832446 @default.
- W2069449301 cites W1978080273 @default.
- W2069449301 cites W1980835422 @default.
- W2069449301 cites W1983621021 @default.
- W2069449301 cites W1983760732 @default.
- W2069449301 cites W1984833612 @default.
- W2069449301 cites W1990705127 @default.
- W2069449301 cites W1992661527 @default.
- W2069449301 cites W1995028702 @default.
- W2069449301 cites W1996544895 @default.
- W2069449301 cites W1996552399 @default.
- W2069449301 cites W1996600303 @default.
- W2069449301 cites W2000742360 @default.
- W2069449301 cites W2002938738 @default.
- W2069449301 cites W2012253653 @default.
- W2069449301 cites W2012852444 @default.
- W2069449301 cites W2013029269 @default.
- W2069449301 cites W2013564192 @default.
- W2069449301 cites W2013984355 @default.
- W2069449301 cites W2014643729 @default.
- W2069449301 cites W2020523694 @default.
- W2069449301 cites W2020656831 @default.
- W2069449301 cites W2021330300 @default.
- W2069449301 cites W2022932023 @default.
- W2069449301 cites W2023234945 @default.
- W2069449301 cites W2023699475 @default.
- W2069449301 cites W2023723598 @default.
- W2069449301 cites W2024789639 @default.
- W2069449301 cites W2029896049 @default.
- W2069449301 cites W2030452489 @default.
- W2069449301 cites W2030627370 @default.
- W2069449301 cites W2035056966 @default.
- W2069449301 cites W2039588955 @default.
- W2069449301 cites W2047534454 @default.
- W2069449301 cites W2050413041 @default.
- W2069449301 cites W2050624503 @default.
- W2069449301 cites W2055942941 @default.
- W2069449301 cites W2056648773 @default.
- W2069449301 cites W2063853621 @default.
- W2069449301 cites W2070112905 @default.
- W2069449301 cites W2070331984 @default.
- W2069449301 cites W2072104730 @default.
- W2069449301 cites W2080147366 @default.
- W2069449301 cites W2088348963 @default.
- W2069449301 cites W2091493430 @default.
- W2069449301 cites W2095522184 @default.
- W2069449301 cites W2096028378 @default.
- W2069449301 cites W2096134439 @default.
- W2069449301 cites W2098382673 @default.
- W2069449301 cites W2100184560 @default.
- W2069449301 cites W2100997502 @default.
- W2069449301 cites W2102537088 @default.
- W2069449301 cites W2103029594 @default.
- W2069449301 cites W2104514360 @default.
- W2069449301 cites W2107853873 @default.
- W2069449301 cites W2109113725 @default.
- W2069449301 cites W2111247260 @default.
- W2069449301 cites W2115019673 @default.
- W2069449301 cites W2115594775 @default.
- W2069449301 cites W2121122463 @default.
- W2069449301 cites W2121785313 @default.
- W2069449301 cites W2122242925 @default.
- W2069449301 cites W2122279751 @default.
- W2069449301 cites W2125024490 @default.
- W2069449301 cites W2129790170 @default.
- W2069449301 cites W2132381095 @default.
- W2069449301 cites W2134355273 @default.
- W2069449301 cites W2134820450 @default.
- W2069449301 cites W2138368121 @default.
- W2069449301 cites W2142386661 @default.
- W2069449301 cites W2143062318 @default.
- W2069449301 cites W2143674709 @default.
- W2069449301 cites W2149375007 @default.
- W2069449301 cites W2150238019 @default.
- W2069449301 cites W2155066067 @default.
- W2069449301 cites W2160621818 @default.
- W2069449301 cites W2160638301 @default.
- W2069449301 cites W2166238056 @default.
- W2069449301 cites W2166336441 @default.
- W2069449301 cites W2169907889 @default.
- W2069449301 cites W2171773051 @default.
- W2069449301 cites W2244964456 @default.
- W2069449301 cites W2313284959 @default.
- W2069449301 cites W2313923699 @default.
- W2069449301 cites W2332736166 @default.
- W2069449301 cites W2413757436 @default.
- W2069449301 cites W2490019007 @default.
- W2069449301 cites W2963206490 @default.